Regeneron stock fell early Wednesday after U.S. sales of its high-dose Eylea came in below Wall Street's expectations ...

REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition ...

Bayer AG BAYRY reported fourth-quarter 2025 core earnings of 18 cents per American Depositary Receipt (ADR), in line with the Zacks Consensus Estimate. The company reported earnings of 28 cents per ...

May 23 (Reuters) - German drugmaker Bayer (BAYGn.DE), opens new tab on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment ...

We were pleased with Regeneron's performance to start 2026, highlighted by strong commercial execution across our key growth products, continued pipeline progress, a disciplined approach to capital ...

Regeneron eyes Q1 results with Dupixent profits and strong Eylea HD uptake set to offset declining Eylea sales amid rising ...

(RTTNews) - Bayer (BAYZF.PK, BAYRY.PK, BYR.L), a German pharmaceutical and life sciences major, announced that the European Commission has granted a label extension in the European Union for Eylea 8 ...

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing ...

ZURICH (Reuters) - Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease ...